Regimen Revenue and Competitors
Estimated Revenue & Valuation
- Regimen's estimated annual revenue is currently $18M per year.
- Regimen's estimated revenue per employee is $243,000
Employee Data
- Regimen has 74 Employees.
- Regimen grew their employee count by 45% last year.
Regimen's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Co-Founder & Managing Director | Reveal Email/Phone |
2 | Co-Founder & Managing Director | Reveal Email/Phone |
Regimen Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $354.2M | 937 | 6% | N/A | N/A |
#2 | $4.5M | 24 | -14% | N/A | N/A |
#3 | $25.9M | 96 | -14% | N/A | N/A |
#4 | $18M | 74 | -16% | N/A | N/A |
#5 | $10.8M | 50 | 9% | N/A | N/A |
#6 | $32.9M | 122 | 8% | N/A | N/A |
#7 | $187.3M | 555 | 9% | N/A | N/A |
#8 | $417.7M | 1105 | 22% | N/A | N/A |
#9 | $25.9M | 96 | 28% | N/A | N/A |
#10 | $108.7M | 322 | 8% | N/A | N/A |
What Is Regimen?
Regimen is the first effective digital therapeutic for men's most personal health issues, starting with better erections. It has been developed by some of the globally leading researchers and practitioners, together with our clients and has a tremendous effect on our client's most personal health.
keywords:N/A
N/A
Total Funding
74
Number of Employees
$18M
Revenue (est)
45%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Regimen News
The tislelizumab regimen had a manageable safety profile consistent with prior reports. The most common adverse events included leukopenia,...
Ultimately, Federer's regimen is a welcome reminder that gentle, low-impact workouts pay dividends, whether you're an aging athlete or an...
Calm your thoughts with heated yoga flows and meditation, then nourish your body with grain bowls, greens, colorful smoothies, and, of course,...
Other Companies in San Jose
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | N/A | 74 | 45% | N/A |
#2 | $14M | 74 | 28% | N/A |
#3 | $9.7M | 74 | -4% | N/A |
#4 | $13.7M | 74 | 12% | N/A |
#5 | $18.2M | 75 | N/A | N/A |